Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 7/20 | 0.49 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.49 |
| ▸ | CXCR2 | P25025 | 4/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2262065 | 0.79 | CCR1 (0.40) | LPLLIPGP2RX7FFAR1DGAT1 | |
| SCHEMBL9940656 | 0.78 | LPL (0.34) | LPLLIPGP2RX7FFAR1DGAT1 | |
| SCHEMBL25243329 | 0.78 | PTK2 (0.36) | LPLLIPGP2RX7FFAR1 | |
| SCHEMBL9940819 | 0.78 | LPL (0.34) | LPLLIPGP2RX7FFAR1DGAT1 | |
| SCHEMBL18840586 | 0.78 | LPL (0.34) | LPLLIPGP2RX7FFAR1DGAT1 | |
| SCHEMBL14235124 | 0.77 | LIPE (0.42) | LPLLIPG | |
| SCHEMBL14718821 | 0.75 | SNCA (0.39) | LPLLIPGDGAT1 | |
| SCHEMBL23170259 | 0.75 | LPL (0.45) | LPLLIPGDGAT1 | |
| SCHEMBL14235345 | 0.74 | ALDH1A1 (0.39) | LPLLIPGDGAT1 | |
| SCHEMBL21484364 | 0.74 | LPL (0.40) | LPLLIPGFFAR1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4458820-A1 | CLASS OF QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2024-11-06 | — | — | EP | disclosed |
| WO-2023125716-A1 | CLASS OF QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 中国科学院上海药物研究所 | 2023-07-06 | — | — | WO | disclosed |
| CN-116354934-A | Quinoline compound, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2023-06-30 | — | — | CN | disclosed |
| CN-110713489-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-05-31 | — | — | CN | disclosed |
| CN-110183440-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-04-22 | — | — | CN | disclosed |
| US-10947243-B2 | Heteroaryl SYK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| CN-110713489-A | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2020-01-21 | — | — | CN | disclosed |
| EP-3119765-B1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-07-17 | — | — | EP | disclosed |
| EP-2215049-B1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2019-06-12 | — | — | EP | disclosed |
| EP-3119772-B1 | HETEROARYL SIK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-05-22 | — | — | EP | disclosed |
| EP-2146986-B1 | DIPHENYL-DIHYDRO-IMIDAZOPYRIDINONES | HOFFMANN LA ROCHE (CH) | 2011-06-29 | — | — | EP | disclosed |
| WO-2010125101-A1 | 5,6,7,8-TETRAHYDROIMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | WO | disclosed |
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2010-10-21 | — | — | US | disclosed |
| US-20100240678-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2010-09-23 | — | — | US | disclosed |
| EP-2215049-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | Merck Sharp & Dohme Corp. (US) | 2010-08-11 | — | — | EP | disclosed |
| US-20090253684-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2009-10-08 | — | — | US | disclosed |
| US-20090227603-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2009-09-10 | — | — | US | disclosed |
| WO-2009058298-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK & CO., INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| US-20090054466-A1 | Leukotriene B4 Inhibitors | DOMINIQUE ROMYR | 2009-02-26 | — | — | US | disclosed |
| EP-1479685-A1 | Process for the preparation of pyridine-2-boronic acid esters | Clariant GmbH (DE) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253684-A1 | LEUKOTRIENE B4 INHIBITORS | LTB4R2, LTB4R, LTC4S | LPL 87/4885LIPG 126/4885CXCR2 550/4885 |
| US-20090227603-A1 | LEUKOTRIENE B4 INHIBITORS | LTB4R2, LTB4R, LTC4S | LPL 81/4885LIPG 121/4885CXCR2 511/4885 |
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | LPL 3674/4885LIPG 4203/4885CXCR2 119/4885 |
| US-20090054466-A1 | Leukotriene B4 Inhibitors | LTB4R2, LTB4R, LTC4S | LPL 81/4885LIPG 121/4885CXCR2 511/4885 |
| US-20100240678-A1 | LEUKOTRIENE B4 INHIBITORS | LTB4R2, LTB4R, LTC4S | LPL 81/4885LIPG 121/4885CXCR2 511/4885 |
| US-10947243-B2 | Heteroaryl SYK inhibitors | SYK, BTK, CD40 | LPL 4010/4885LIPG 2256/4885CXCR2 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.